0001663577-26-000141
SEC filingRevenue and gross profit remained flat at $5.0K, consistent with Skinvisible’s pre-commercial licensing model; operating and net losses narrowed modestly year-over-year, while operating cash outflows improved dramatically to -$822 from -$31.7K — reflecting timing-driven working capital dynamics rather than operational inflection.
Revenue and gross profit each remained unchanged at $5.0K for Q1 FY2026 versus Q1 FY2025. This stability reflects Skinvisible’s business model: it generates revenue solely through licensing arrangements, with no product manufacturing, distribution, or direct sales. As stated in the business context, 'the demand for our products is enhanced due to the granting of key US and international patents and the completed development of a number of unique products' — yet monetization remains contingent on licensee commercial activity. Royalties do not accrue upon clinical milestones, regulatory designations, or trial expansions; they trigger only upon commercial sales by licensees such as Quoin. Accordingly, flat top-line metrics are expected and structurally aligned with the company’s stage.
Gross margin remained at 100%, consistent with management’s disclosure that 'Cost of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies' — none of which apply to Skinvisible’s pure licensing revenue stream. The company explicitly states that 'Shipping and handling costs is not a significant portion of the cost of revenue', reinforcing that licensing fees carry zero associated cost of goods sold. All expenses — including those supporting Quoin’s Netherton Syndrome program — are reported within operating expenses, preserving the 100% gross margin.
Operating income improved to -$125.9K from -$139.9K (a 9.9% narrowing), and net income improved to -$267.2K from -$281.0K (a 4.9% narrowing). These improvements are quantitatively supported by XBRL data but lack itemized driver disclosure in the authoritative packet. Management notes that 'our operating expenses for all periods consisted mainly of selling, general and administrative expenses', and further states 'we expect our operating expenses will increase in the future as the Company begins to generate more licensing revenue'. The current reduction therefore reflects baseline expense discipline — not new revenue — and does not signal an inflection toward profitability.
Quoin’s clinical progress remains the central value driver: the ongoing Phase 2 and pediatric investigator studies for QRX003, along with plans to request a Type C meeting with the FDA to align on Phase 3 design, constitute the only near-term pathway to royalty revenue. No assurance is provided that capital will be raised successfully, and no guidance is given on timing of commercial launch or royalty commencement.